Adding radiation therapy or surgery to the primary tumor does not improve progression-free survival in men already receiving best systemic therapy for de novo metastatic prostate cancer, a phase 2 ...
Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with mCSPC ...
Triplet versus doublet therapy in older patients with metastatic hormone-sensitive prostate cancer: A network meta-analysis. 8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen ...
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...
By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer ...
Novel prostate cancer treatment can reduce risk of disease progression by half, clinical trial shows
A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer Institute and professor of internal medicine at the University of Utah (the U), has ...
AVENTURA, Fla. — Burley Brewton was able to count on a new advancement in targeted therapy after he was diagnosed with prostate cancer, the second most common cancer in men. Brewton, 66, who is among ...
(UroToday.com) The 2026 SNMMI annual meeting featured a genitourinary diagnosis and imaging session and a presentation by Molly Wynveen discussing survival in Veterans with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results